Secondary hypertension
Methodology & AI Transparency ⓘ
Secondary hypertension Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Secondary hypertension is an ICD-10-CM indexed diagnosis (I15.9) within High Blood Pressure & Vascular Health.
- 2 Real-world patient consensus: Federal ICD-10-CM code I15.9 categorizes Secondary hypertension under High Blood Pressure & Vascular Health.
- 3 Typical cash cost range: Clinicians assessing Secondary hypertension focus on venous valve incompetence [Secondary hypertension I15.9] and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Secondary hypertension: maintaining Home Seated Blood in Secondary hypertension (I15.9: Pressure) within < 120/75 mmHg (I15.9).
Ask our AI Specialists anything about Secondary hypertension
What Is Secondary hypertension?
Secondary hypertension is an ICD-10-CM indexed diagnosis (I15.9) within High Blood Pressure & Vascular Health. Clinical evaluation centers on renal-electrolyte panels [Secondary hypertension I15.9] alongside serial Home Seated Blood in Secondary hypertension (I15.9: Pressure) tracking (< 120/75 mmHg (I15.9)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Secondary hypertension (I15.9) features venous valve incompetence [Secondary hypertension I15.9]. therapeutic stabilization in blood pressure is verified against Ankle-Brachial Index (ABI) [Secondary hypertension I15.9].
Common Symptoms & Clinical Signs
- • Presentation of Secondary hypertension (I15.9): persistently elevated home in Secondary hypertension (I15.9: or clinic blood)
- • Secondary Secondary hypertension clinical sign: morning occipital headache, in Secondary hypertension (I15.9: pulsatile tinnitus, or)
- • Symptom flares in Secondary hypertension correlating with Home Seated Blood in Secondary hypertension (I15.9: Pressure) deviation outside < 120/75 mmHg (I15.9)
- • Functional blood pressure impact requiring renal-electrolyte panels [Secondary hypertension I15.9] evaluation (I15.9)
Secondary hypertension Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I15.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Home Seated Blood in Secondary hypertension (I15.9: Pressure) | < 120/75 mmHg (I15.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Secondary hypertension I15.9] | 1.00 – 1.30 (I15.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Creatinine & in Secondary hypertension (I15.9: Potassium) | K+ 4.0 – 4.8 mEq/L (I15.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Secondary hypertension
Treatment selection for Secondary hypertension depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Secondary hypertension)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Heart and blood vessel outcomes in high-risk hypertensive patients stratified by: What a 8,126-Participant Study Found Older high-risk patients with high blood pressure and reduced GFR are more likely to develop CHD than to develop ESRD. Annals of internal medicine • 2006-02-07 • Randomized Controlled Trial | N = 8,126 | 96/100 | PMID 16461961 ↗ |
| New Insights on Reductions in acute medication use and healthcare resource utilization in: What a 1,113-Participant Study Found Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU. Journal of medical economics • 2022-01-15 • Phase III Randomized Trial | N = 1,113 | 96/100 | PMID 35971655 ↗ |
| New Insights on Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of: What a 1,156-Participant Study Found After accounting for therapeutic lag and differences between ASCEND and SPECTRIMS trials, natalizumab, compared. Journal of neurology, neurosurgery, and psychiatry • 2025-09-12 • Phase III Randomized Trial | N = 1,156 | 96/100 | PMID 40050011 ↗ |
| New Insights on Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary: What a 1,012-Participant Study Found This analysis showed that reductions in pain were significantly mediated by reductions in HMB (all doses) and FV (200 mg alone) in linzagolix-treated women with UFs. BJOG : an international journal of obstetrics and gynaecology • 2025-08-15 • Phase III Randomized Trial | N = 1,012 | 96/100 | PMID 40326221 ↗ |
| New Insights on Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among: What a 2,174-Participant Study Found All medications were generally safe in both MDD cohorts. The American journal of psychiatry • 2025-02-01 • Randomized Controlled Trial | N = 2,174 | 96/100 | PMID 39659160 ↗ |
Secondary hypertension Patient Community & “People Like Me” Threads
Filter Secondary hypertension community threads and patient logs by age, biological sex, dosage, and treatment duration.